Assessing BioNTech (NasdaqGS:BNTX) Valuation After Recent Share Price Momentum

Simply Wall St.04-20

BioNTech (BNTX) is back in focus after recent trading, with the share price closing at US$102.92 and short term returns mixed, including a roughly 15% gain over the past month. See our latest analysis...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2628721426?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-20 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628721426","market":"nz","top_or_hot":-1,"title":"Assessing BioNTech (NasdaqGS:BNTX) Valuation After Recent Share Price Momentum","media":"Simply Wall St.","content":"<div>\n<p>BioNTech (BNTX) is back in focus after recent trading, with the share price closing at US$102.92 and short term returns mixed, including a roughly 15% gain over the past month. See our latest analysis...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bntx/biontech/news/assessing-biontech-nasdaqgsbntx-valuation-after-recent-share\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing BioNTech (NasdaqGS:BNTX) Valuation After Recent Share Price Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing BioNTech (NasdaqGS:BNTX) Valuation After Recent Share Price Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-20 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bntx/biontech/news/assessing-biontech-nasdaqgsbntx-valuation-after-recent-share><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech (BNTX) is back in focus after recent trading, with the share price closing at US$102.92 and short term returns mixed, including a roughly 15% gain over the past month. See our latest analysis...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bntx/biontech/news/assessing-biontech-nasdaqgsbntx-valuation-after-recent-share\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bntx/biontech/news/assessing-biontech-nasdaqgsbntx-valuation-after-recent-share","article_id":"2628721426","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bntx/biontech/news/assessing-biontech-nasdaqgsbntx-valuation-after-recent-share","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2628721426","pubTimestamp":1776693949,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BioNTech (BNTX) is back in focus after recent trading, with the share price closing at US$102.92 and short term returns mixed, including a roughly 15% gain over the past month.\nSee our latest analysis for BioNTech.\nThe recent 6.4% 7 day share price return and roughly 15% 1 month share price return contrast with a modest 1.1% 1 year total shareholder return, suggesting short term momentum after a mixed multi year experience.\nIf BioNTech's recent move has sharpened your interest in healthcare...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4588":"碎股","BNTX":"BioNTech SE","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","BK4139":"生物科技","BK4551":"寇图资本持仓"},"translate_title":"在近期股价势头后评估BioNTech（纳斯达克GS：BNTX）的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1.5},"content_text":"BioNTech (BNTX) is back in focus after recent trading, with the share price closing at US$102.92 and short term returns mixed, including a roughly 15% gain over the past month. See our latest analysis for BioNTech. The recent 6.4% 7 day share price return and roughly 15% 1 month share price return contrast with a modest 1.1% 1 year total shareholder return, suggesting short term momentum after a mixed multi year experience. If BioNTech's recent move has sharpened your interest in healthcare and biotech, it could be a good moment to look across other potential healthcare AI opportunities via the 37 healthcare AI stocks. With BioNTech valued at about US$26b, reporting revenue of €2,869.9m and a net loss of €1,136.1m, the key question is whether recent share price strength reflects a bargain or if markets already price in expectations for future growth. AdvertisementMost Popular Narrative: 79.4% Undervalued Compared with the last close at $102.92, the most followed narrative points to a fair value of about $499.94, framing BioNTech as heavily undervalued on that view.  \"Amputation, intoxication and radiation\". If students read about our current cancer treatment in 2050, they would probably date it back to 1960-70. Certainly not dating back to the time of AI, fusion reactors or recurring missiles.  Read the complete narrative. According to Hansimglueck, this valuation leans on fast expanding oncology revenue, rising margins and a future profit multiple more often associated with mature, high quality franchises. The real story sits in how those assumptions stack up against current losses and revenue trends. The full narrative joins those moving parts into a single price tag of almost $500 per share. Result: Fair Value of $499.94 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there are clear risks here, including the current €1,136.1m net loss and the uncertainty around how oncology trial outcomes will translate into sustainable revenue. Find out about the key risks to this BioNTech narrative. Next Steps Looking for more investment ideas? If BioNTech has caught your attention, do not stop there. Use the Simply Wall St screener to quickly spot other opportunities that fit your investing style.  Target resilient income by checking out companies offering 12 dividend fortresses that might suit investors who value regular cash returns. Hunt for quality at a sensible price with the 60 high quality undervalued stocks and see which businesses currently trade below their estimated worth. Prioritise capital protection by reviewing the 71 resilient stocks with low risk scores to focus on companies with relatively lower risk profiles.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if BioNTech might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2628721426","isCrawlerRequest":true}